Table of Contents Author Guidelines Submit a Manuscript
Behavioural Neurology
Volume 2014, Article ID 917246, 7 pages
http://dx.doi.org/10.1155/2014/917246
Research Article

Modafinil Effects on Behavior and Oxidative Damage Parameters in Brain of Wistar Rats

1Laboratório de Neurociências, Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806000 Criciúma, SC, Brazil
2Center for Experimental Models in Psychiatry, Department of Psychiatry and Behavioral Sciences, The University of Texas Medical School at Houston, Houston, TX 77054, USA

Received 8 May 2014; Accepted 9 August 2014; Published 6 November 2014

Academic Editor: Antonio Pisani

Copyright © 2014 Felipe Ornell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. J. Minzenberg and C. S. Carter, “Modafinil: a review of neurochemical actions and effects on cognition,” Neuropsychopharmacology, vol. 33, no. 7, pp. 1477–1502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. F. T. Arnsten and J. X. Cai, “Postsynaptic alpha-2 receptor stimulation improves memory in aged monkeys: indirect effects of yohimbine versus direct effects of clonidine,” Neurobiology of Aging, vol. 14, no. 6, pp. 597–603, 1993. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Béracochéa, B. Cagnard, A. Célérier, J. Le Merrer, M. Pérès, and C. Piérard, “First evidence of a delay-dependent working memory-enhancing effect of modafinil in mice,” NeuroReport, vol. 12, no. 2, pp. 375–378, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. C. P. Ward, J. R. Harsh, K. M. York, K. L. Stewart, and J. G. McCoy, “Modafinil facilitates performance on a delayed nonmatching to position swim task in rats,” Pharmacology Biochemistry and Behavior, vol. 78, no. 4, pp. 735–741, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. R. Harsh, R. Hayduk, R. Rosenberg et al., “The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy,” Current Medical Research and Opinion, vol. 22, no. 4, pp. 761–774, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Piérard, P. Liscia, M. Valleau et al., “Modafinil-induced modulation of working memory and plasma corticosterone in chronically-stressed mice,” Pharmacology Biochemistry and Behavior, vol. 83, no. 1, pp. 1–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. F. T. Arnsten, “Adrenergic targets for the treatment of cognitive deficits in schizophrenia,” Psychopharmacology, vol. 174, no. 1, pp. 25–31, 2004. View at Google Scholar · View at Scopus
  8. T. S. Braver, D. M. Barch, and J. D. Cohen, “Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function,” Biological Psychiatry, vol. 46, no. 3, pp. 312–328, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. D. C. Turner, L. Clark, J. Dowson, T. W. Robbins, and B. J. Sahakian, “Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder,” Biological Psychiatry, vol. 55, no. 10, pp. 1031–1040, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. S. Ballon and D. Feifel, “A systematic review of modafinil: potential clinical uses and mechanisms of action,” Journal of Clinical Psychiatry, vol. 67, no. 4, pp. 554–566, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Wolf, U. Fiedler, I. Anghelescu, and N. Schwertfeger, “Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil,” Journal of Clinical Psychiatry, vol. 67, no. 11, p. 1817, 2006. View at Google Scholar · View at Scopus
  12. J. M. Pierre, J. H. Peloian, D. A. Wirshing, W. C. Wirshing, and S. R. Marder, “A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia,” The Journal of Clinical Psychiatry, vol. 68, no. 5, pp. 705–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. N. D. Volkow, J. S. Fowler, J. Logan et al., “Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications,” The Journal of the American Medical Association, vol. 301, no. 11, pp. 1148–1154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. W. Young, K. Kooistra, and M. A. Geyer, “Dopamine receptor mediation of the exploratory/hyperactivity effects of modafinil,” Neuropsychopharmacology, vol. 36, no. 7, pp. 1385–1396, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. B. M. Angrist and S. Gershon, “The phenomenology of experimentally induced amphetamine psychosis—preliminary observations,” Biological Psychiatry, vol. 2, no. 2, pp. 95–107, 1970. View at Google Scholar · View at Scopus
  16. E. H. Ellinwood Jr., A. Sudilovsky, and L. M. Nelson, “Evolving behavior in the clinical and experimental amphetamine (model) psychosis,” American Journal of Psychiatry, vol. 130, no. 10, pp. 1088–1093, 1973. View at Google Scholar · View at Scopus
  17. R. C. Hall, M. K. Popkin, T. P. Beresford, and A. K. Hall, “Amphetamine psychosis: clinical presentations and differential diagnosis,” Psychiatric Medicine, vol. 6, no. 1, pp. 73–79, 1988. View at Google Scholar · View at Scopus
  18. B. N. Frey, S. S. Valvassori, K. M. Gomes et al., “Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure,” Brain Research, vol. 1097, no. 1, pp. 224–229, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. R. Jasinski, “An evaluation of the abuse potential of modafinil using methylphenidate as a reference,” Journal of Psychopharmacology, vol. 14, no. 1, pp. 53–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. R. A. Floyd, “Antioxidants, oxidative stress, and degenerative neurological disorders,” Proceedings of the Society for Experimental Biology and Medicine, vol. 222, no. 3, pp. 236–245, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. A. C. Andreazza, B. N. Frey, S. S. Valvassori et al., “DNA damage in rats after treatment with methylphenidate,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 6, pp. 1282–1288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. A. C. Andreazza, M. Kauer-Sant'Anna, B. N. Frey et al., “Effects of mood stabilizers on DNA damage in an animal model of mania,” Journal of Psychiatry and Neuroscience, vol. 33, no. 6, pp. 516–524, 2008. View at Google Scholar · View at Scopus
  23. S. S. Valvassori, F. C. Petronilho, G. Z. Réus et al., “Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 32, no. 4, pp. 1064–1068, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. S. Valvassori, G. T. Rezin, C. L. Ferreira et al., “Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine,” Journal of Psychiatric Research, vol. 44, no. 14, pp. 903–909, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. K. M. Gomes, F. C. Petronilho, M. Mantovani et al., “Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats,” Neurochemical Research, vol. 33, no. 6, pp. 1024–1027, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. K. M. Gomes, C. G. Inácio, S. S. Valvassori et al., “Superoxide production after acute and chronic treatment with methylphenidate in young and adult rats,” Neuroscience Letters, vol. 465, no. 1, pp. 95–98, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. D. da-Rosa, S. S. Valvassori, A. V. Steckert et al., “Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats,” Journal of Neural Transmission, vol. 119, no. 1, pp. 31–38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. M. Barros, L. A. Izquierdo, J. H. Medina, and I. Izquierdo, “Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats,” Behavioural Pharmacology, vol. 13, no. 3, pp. 215–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. H. H. Draper and M. Hadley, “Malondialdehyde determination as index of lipid peroxidation,” Methods in Enzymology, vol. 186, pp. 421–431, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. R. L. Levine, J. A. Williams, E. R. Stadtman, and E. Shacter, “Carbonyl assays for determination of oxidatively modified proteins,” Methods in Enzymology, vol. 233, pp. 346–357, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. M. L. Andersen, E. Kessler, K. S. Murnane, J. C. McClung, S. Tufik, and L. L. Howell, “Dopamine transporter-related effects of modafinil in rhesus monkesy,” Psychopharmacology, vol. 210, no. 3, pp. 439–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. R. M. Vianna, M. Alonso, H. Viola et al., “Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat,” Learning and Memory, vol. 7, no. 5, pp. 333–340, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. J.-F. Hermant, F. A. Rambert, and J. Duteil, “Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macaca mulatta) after acute and repeated administration,” Psychopharmacology, vol. 103, no. 1, pp. 28–32, 1991. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Simon, C. Panissaud, and J. Costentin, “The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine,” Psychopharmacology, vol. 114, no. 4, pp. 597–600, 1994. View at Publisher · View at Google Scholar · View at Scopus
  35. S. A. M. van Vliet, M. J. Jongsma, R. A. P. Vanwersch, B. Olivier, and I. H. C. H. M. Philippens, “Behavioral effects of modafinil in marmoset monkeys,” Psychopharmacology, vol. 185, no. 4, pp. 433–440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. P. M. Becker, J. R. L. Schwartz, N. T. Feldman, and R. J. Hughes, “Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy,” Psychopharmacology, vol. 171, no. 2, pp. 133–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Saletu, P. Anderer, H. V. Semlitsch et al., “Low-resolution brain electromagnetic tomography (LORETA) identifies brain regions linked to psychometric performance under modafinil in narcolepsy,” Psychiatry Research, vol. 154, no. 1, pp. 69–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. E. R. Samuels, R. H. Hou, R. W. Langley, E. Szabadi, and L. M. Bradshaw, “Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers,” Journal of Psychopharmacology, vol. 20, no. 6, pp. 756–770, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. R. L. Schwartz, M. Hirshkowitz, M. K. Erman, and W. Schmidt-Nowara, “Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study,” Chest, vol. 124, no. 6, pp. 2192–2199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. I. Taneja, K. Haman, R. C. Shelton, and D. Robertson, “A randomized, double-blind, crossover trial of modafinil on mood,” Journal of Clinical Psychopharmacology, vol. 27, no. 1, pp. 76–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Rasetti, V. S. Mattay, B. Stankevich et al., “Modulatory effects of modafinil on neural circuits regulating emotion and cognition,” Neuropsychopharmacology, vol. 35, no. 10, pp. 2101–2109, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. R. Hariri, V. S. Mattay, A. Tessitore, F. Fera, W. G. Smith, and D. R. Weinberger, “Dextroamphetamine modulates the response of the human amygdala,” Neuropsychopharmacology, vol. 27, no. 6, pp. 1036–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. B. K. Madras, Z. Xie, Z. Lin et al., “Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 2, pp. 561–569, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. W.-M. Qu, Z.-L. Huang, X.-H. Xu, N. Matsumoto, and Y. Urade, “Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil,” Journal of Neuroscience, vol. 28, no. 34, pp. 8462–8469, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. J. F. Zhou, P. Chen, Y. H. Zhou, L. Zhang, and H. H. Chen, “3,4-Methylenedioxymethamphetamine (MDMA) abuse may cause oxidative stress and potential free radical damage,” Free Radical Research, vol. 37, no. 5, pp. 491–497, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Z. Wrona, Z. Yang, F. Zhang, and G. Dryhurst, “Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration,” NIDA Research Monograph, vol. 173, pp. 146–174, 1997. View at Google Scholar · View at Scopus
  47. U. A. Zifko, M. Rupp, S. Schwarz, H. T. Zipko, and E. M. Maida, “Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study,” Journal of Neurology, vol. 249, no. 8, pp. 983–987, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Kim, “Practical use and risk of modafinil, a novel waking drug,” Environmental Health and Toxicology, vol. 27, Article ID e2012007, 2012. View at Publisher · View at Google Scholar
  49. J. A. Aguirre, A. Cintra, J. Hillion et al., “A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse,” Neuroscience Letters, vol. 275, no. 3, pp. 215–218, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. S. A. M. van Vlieta, E. L. A. Blezer, M. J. Jongsma, R. A. P. Vanwersch, B. Olivier, and I. H. C. H. M. Philippens, “Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy,” Brain Research, vol. 1189, no. 1, pp. 219–228, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. C. M. M. Santos, “New agents promote neuroprotection in Parkinson's disease models,” CNS and Neurological Disorders: Drug Targets, vol. 11, no. 4, pp. 410–418, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Raineri, V. Peskin, B. Goitia et al., “Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice,” Synapse, vol. 65, no. 10, pp. 1087–1098, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. D. G. Ghahremani, G. Tabibnia, J. Monterosso, G. Hellemann, R. A. Poldrack, and E. D. London, “Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals,” Neuropsychopharmacology, vol. 36, no. 5, pp. 950–959, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. N. M. Doig, J. Moss, and J. P. Bolam, “Cortical and thalamic innervation of direct and indirect pathway medium-sized spiny neurons in mouse striatum,” Journal of Neuroscience, vol. 30, no. 44, pp. 14610–14618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. H. M. Bayer and P. W. Glimcher, “Midbrain dopamine neurons encode a quantitative reward prediction error signal,” Neuron, vol. 47, no. 1, pp. 129–141, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Willuhn and H. Steiner, “Motor-skill learning in a novel running-wheel task is dependent on D1 dopamine receptors in the striatum,” Neuroscience, vol. 153, no. 1, pp. 249–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Calabresi, P. Gubellini, D. Centonze et al., “Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity,” Journal of Neuroscience, vol. 20, no. 22, pp. 8443–8451, 2000. View at Google Scholar · View at Scopus
  58. V. Pawlak and J. N. D. Kerr, “Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity,” Journal of Neuroscience, vol. 28, no. 10, pp. 2435–2446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. J. I. Rossato, L. R. M. Bevilaqua, I. Izquierdo, J. H. Medina, and M. Cammarota, “Dopamine controls persistence of long-term memory storage,” Science, vol. 325, no. 5943, pp. 1017–1020, 2009. View at Publisher · View at Google Scholar · View at Scopus